International natural history studies
He co-chairs the CINRG Duchenne Natural History Study and the expanded eDNHS. These long-term datasets describe how DMD progresses and supply external comparison data for many drug development programs.
Building the evidence base for rare neuromuscular disease therapies, from international natural history studies and clinical trial endpoints to AI-driven, real-world measures of mobility.
EH
Erik Henricson is a Professor in the Department of Physical Medicine and Rehabilitation at UC Davis, where he serves as Interim Vice Chair for Research and Associate Director for Clinical Research of the Neuromuscular Research Center.
He has studied Duchenne muscular dystrophy (DMD) since the late 1990s. As co-founder and Director of Operations of the Cooperative International Neuromuscular Research Group (CINRG), he helped build one of the field's longest-running natural history studies. Researchers, industry, and regulators around the world use its data to design trials and evaluate new therapies.
His work covers multicenter international trials in pediatric rare diseases, disease epidemiology, clinical trial outcome measures and biomarkers, study design, and person-reported outcomes of mobility and daily activity. His current research uses wearable and mobile-device sensors with machine learning to measure how people move in their communities, outside the clinic.
He is also a long-serving leader in research ethics and regulatory science at UC Davis. He chairs and vice-chairs Institutional Review Board committees, and he directed the Regulatory Knowledge and Support program of the Clinical and Translational Science Center from 2017 to 2026.
He co-chairs the CINRG Duchenne Natural History Study and the expanded eDNHS. These long-term datasets describe how DMD progresses and supply external comparison data for many drug development programs.
He helped establish the 6-minute walk test, the Performance of the Upper Limb (PUL) module, and timed function tests as reliable, clinically meaningful endpoints for DMD trials.
He leads ROAM-AI (NSF) and Walk4Me, which apply machine and deep learning to accelerometer data to measure gait, steps, and travel distance in children's daily lives.
He developed the DMD Lifetime Mobility Scale and applies Rasch and bioecological frameworks to quality of life, function, and participation across the lifespan.
His collaborative work on serum protein biomarkers and on genetic modifiers of disease severity (SPP1, LTBP4) helps explain why DMD varies so much from person to person.
He provides IRB leadership, oversees research compliance, and serves on the Critical Path Institute's Duchenne Regulatory Science Consortium.
2026 shows citations through October (year to date).
Selected from more than 136 peer-reviewed articles in The Lancet, JAMA, PNAS, Neurology, Annals of Neurology, Muscle & Nerve, Sensors, and other journals.
Funders include the NSF, NIH (NINDS, NIAMS, NIDDK), the U.S. Department of Defense, the U.S. Department of Education, the Muscular Dystrophy Association, CITRIS, and industry partners.
HOPE-2: CAP-1002 in ambulatory and non-ambulatory patients with DMD
A community-based gait monitor for children with DMD
6-minute walk test: 48-week multicenter natural history observations
Also recognized in 2008 (×2) and 2009 (×2)
FAACPDM
Energy expenditure estimation using smartphone body sensors
He teaches graduate and undergraduate courses in clinical research methods and has mentored doctoral students, postdoctoral scholars, residents, and fellows who now hold faculty and leadership positions.
He welcomes inquiries about research collaborations, natural history data, digital outcome measures, mentoring, and speaking invitations.